PARIS, FRANCE / ACCESSWIRE / October 19, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative
Investegate announcements from Pharnext, Pharnext strengthens its management team with three key appointments to support ongoing development of PXT3003 toward approval and commercialization